Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
株式のランク #17309
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
株価
$1.21
時価総額
$248.41M
変化(1日)
4.11%
変化(1年)
79.12%
TW
取引 TWi Biotechnology, Inc. (6610)

カテゴリー

TWi Biotechnology, Inc.(6610)の株価履歴
終値の最高値: $1.18 (2026-09-01)

終値の最安値: $1.95 (2016-12-01)
TWi Biotechnology, Inc. の株価履歴(2016 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) 43.11%
2025 36.47%
2024 -13.49%
2023 13.07%
2022 -19.33%
2021 0.82%
2020 81.49%
2019 -54.47%
2018 -43.81%
2017 -42.56%
2016 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$554.04 38.16%
US
$1.05K 48.01%
NL
$148.48 513.79%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH